SEOUL-SEMICONDUCTOR
13.10.2021 10:02:04 CEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED technology, announced that its SunLike Series natural spectrum LEDs, which implement light that closely matches the spectrum of sunlight, has been adopted by Global lighting brand LEDVANCE for its new family of products Sun@Home.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211013005089/en/
Sun@Home is a premium product line that delivers residential lighting with the best quality of the light. After more than a year of Covid workers and employees are spending much more time in home office work and light is key for having the right environment to be comfortable, concentrated and relax at the same time. SunLike technology is proven to deliver the best light quality for humans. Sun@Home products are all equipped with a smart controller that allows the light to adapt the spectrum to the required needs of the user. SunLike is the only LED that is capable to simulate the Sunlight spectrum from the early morning to sunset when the Sun goes down. The state-of-the-art automated wireless system from LEDVANCE makes it easy to control and adjust the different working modes and light spectrums to stimulate the user in the right way depending on the tasks to do. With SunLike Series natural spectrum LEDs, the fixtures and bulbs are designed to bring out the natural color tones of objects achieving a lower blue light peak, similar to the sunlight spectral curve, which enables the reduction of scattered reflection and glare. It also provides healthy and comfortable light, improving the environment for living, reducing eye fatigue, and displaying colors and textures more accurately with CRI 97 and TM30 = 100 for any CCT from 2200K to 5000K range.
There has been a significant increase in research activity on the relationship between light and human bio-functions, including a recent scientific study focused on the effects of light spectrum on sleep quality, visual comfort, overall well-being, and daytime alertness; encompassing the interaction of both visual and non-visual light on humans. Based on the results of a comprehensive sleep study conducted by Professor Christian Cajochen and his colleagues at the University of Basel in Switzerland, SunLike Series natural spectrum LEDs have been identified as a key light source for promoting human well-being. The study, published in the Journal of Lighting & Research Technology on March 24, 2019, found “evidence that a daylight [natural spectrum] LED solution has beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity in healthy volunteers.”
“Seoul Semiconductor’s SunLike Series natural spectrum LEDs have three beneficial effects in contrast to conventional LEDs: Better Sleep – improvement in sleep quality, Better Eye Health – protection from myopia in children; and Better Study – support for students’ learning and concentration,” said Oliver Schäfer, Executive Vice President Europe of Seoul Semiconductor. “Together with LEDVANCE we are starting a new revolution in the consumer market as we are bringing the best available professional light until now reserved to Museums and Premium products to the mass market. Thanks to LEDVANCE and his vision for the future for human centric lighting for indoor design the spectrum of natural sunlight will provide beneficial effects for all humans improving their health and well-being” added him.
SunLike Series LEDs are an advanced technology that has achieved the highest level of eye safety certification from the International Commission on Illumination as a safe light source with no photo-biological risks and is the only LED certified as Diamond Color Rendering Class by the UL laboratories.
https://verify.ul.com/verifications/520
Introduced in June 2017, the SunLike Series natural spectrum LEDs are an advanced light source that combines the latest optical and compound semiconductor technology of Seoul Semiconductor with Toshiba Materials’ TRI-R® technology. TRI-R, supported by Toshiba Materials, finds in the definition “The light closest to the sun for human well-being” its original concept. The sun light spectrum is developed by the same company and can be reproduced by a white LED light source technology.
About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en .
About LEDVANCE
LEDVANCE is one of the world‘s leaders in general lighting for lighting professionals as well as end users, offering a broad variety of LED luminaires, advanced LED lamps, intelligent Smart Home & Smart Building solutions as well as traditional light sources.
Emerged from the general lighting business of OSRAM, the company is now owned by Chinese lighting company MLS Co., LTD. With offices in more than 50 countries and business activities in more than 140 countries, LEDVANCE possesses an outstanding global market access built on trusted, long-standing customer relationships and a powerful distribution network. Based on our in-depth understanding of the general lighting market, trending technologies and changing needs, we support the specific and individual demands of both direct and indirect customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005089/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom